Pharma stocks took big hits in recent years as many of its largest companies saw a looming "patent cliff" that could dry out profits from their big cash-cow drugs. This may be good for smaller pharma companies like one stock, which was one of Chen Lin's top picks for 2024.
This telehealth company is expanding its platform to cover remote monitoring for pediatric patients with diabetes and other eligible conditions. Find out why one analyst says this company's stock is gathering momentum.
This telehealth company has signed a new contract with a Texas respiratory clinic that is expected to add 10,000 new patients to its iUGO platform by mid-2024. Read to see why one analyst believes this stock is a Buy.